A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Assessment of PF-06700841 in participants with moderate to severe active, generalized Systemic Lupus Erythematosus (SLE) that have inadequate response to standard of care.
Inclusion Criteria:
Exclusion Criteria:
San Miguel de Tucumán, Tucumán Province T4000AXL, Argentina
Rimouski, Quebec G5L 5T1, Canada
Barranquilla, Atlántico 080002, Colombia
Bogota, Cundinamarca 110221, Colombia
Bogotá, Cundinamarca 110221, Colombia
Haidari, 12462, Greece
Chuo-ku, Tokyo 104-8560, Japan
Mexico City, Cuauhtémoc 06700, Mexico
Guadalajara, Jalisco 45070, Mexico
Zapopan, Jalisco C.P. 45070, Mexico
Mexico City, Tlalpan 14080, Mexico
Brasov, JUD. Brasov 500283, Romania
Seocho-gu, Seoul 06591, South Korea
Kyiv, 03680, Ukraine
Kyiv, 03680, Ukraine
Ternopil, 46002, Ukraine
Vinnytsia, 21028, Ukraine
Doncaster, DN2 5LT, United Kingdom